Table I.
Patients and tumour characteristics.
| Parameter | IHC (n=243) | RT-qPCR (n=36) |
|---|---|---|
| Mean age, years (range) | 66.40±7.4 (50–84) | 65.29±7.52 (52–77) |
| Sex, n (%) | ||
| Male | 145 (59.67) | 21 (58.33) |
| Female | 98 (40.33) | 15 (41.67) |
| Tumour size, n (%) | ||
| T1 | 76 (31.28) | 8 (22.22) |
| T2 | 124 (51.03) | 20 (55.56) |
| T3 | 24 (9.88) | 5 (13.89) |
| T4 | 5 (2.06) | 1 (2.78) |
| No data | 14 (5.76) | 2 (5.56) |
| Lymph nodes, n (%) | ||
| N0 | 147 (60.49) | 22 (61.11) |
| N1,N2,N3 | 82 (33.74) | 12 (33.33) |
| No data | 14 (5.76) | 2 (5.56) |
| Grade, n (%) | ||
| G1 | 3 (1.23) | 0 (0.00) |
| G2 | 150 (61.73) | 25 (69.44) |
| G3 | 90 (37.04) | 10 (27.78) |
| No data | 0 (0.00) | 1 (2.78) |
| pTNM, n (%) | ||
| I | 104 (42.80) | 15 (41.67) |
| II | 76 (31.28) | 15 (41.67) |
| III | 46 (18.93) | 4 (11.11) |
| IV | 2 (0.82) | 0 (0.00) |
| No data | 15 (6.17) | 2 (5.56) |
| Stage, n (%) | ||
| Early | 180 (74.07) | 30 (83.33) |
| Advanced | 48 (19.75) | 4 (11.11) |
| No data | 15 (6.17) | 2 (5.56) |
| Histology, n (%) | ||
| Adeno | 151 (62.14) | 18 (50.00) |
| SCC | 92 (37.86) | 18 (50.00) |
| p63, n (%) | ||
| Positive | 111 (45.68) | 20 (55.56) |
| Negative | 89 (36.63) | 11 (30.56) |
| No data | 43 (17.70) | 5 (13.89) |
| TTF-1, n (%) | ||
| Positive | 156 (64.20) | 20 (55.56) |
| Negative | 44 (18.11) | 11 (30.56) |
| No data | 43 (17.70) | 5 (13.89) |
| Tesmin IHC, n (%) | ||
| IRS | ||
| 0 | 12 (4.94) | – |
| 1-12 | 231 (95.06) | – |
| Nuclear | ||
| 0 | 40 (16.46) | – |
| 1-4 | 203 (83.54) | – |
IHC, immunohistochemistry; RT-qPCR, reverse transcription-quantitative PCR; TTF-1, thyroid transcription factor 1; IRS, immunoreactive score; SCC, squamous cell carcinoma of the lung.